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Toll-like receptors (TLRs) play a key role in the cross-talk between the innate and adaptive immune systems.
Previous studies investigating associations between certain TLRs and acute graft-versus-host disease (aGVHD)
have reported contrasting results, and no studies relating aGVHD to the expression and function of all human
TLRs together have been published to date. We prospectively evaluated the expression of 9 TLRs on T
lymphocytes and monocytes by ﬂow cytometry in relation to aGVHD in 34 patients. Induction of TNF-a, IL-4,
IFN-g, and monocyte chemotactic protein 1 on TLR activation was assessed by ELISA on cell supernatants.
Nineteen patients developed aGVHD, at a median time of 28 days (range, 20-50 days) after transplantation. A
2-step multivariate analysis was performed using principal component analysis and multifactor analysis of
variance. The levels of TLR-5 expression on monocytes and T lymphocytes were positively correlated to
aGVHD (P ¼ .01), whereas levels of TLR-1 and -9 were negative predictors (P ¼ .03 and .01, respectively). This
proﬁle of TLR-1, -5, and -9 can promote an overall immunostimulatory/proinﬂammatory response. If our
ﬁndings are conﬁrmed by further studies, this TLR proﬁle could be a useful biomarker of aGVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION pathogen-derivedmolecules and products of damaged tissues
Acute graft-versus-host disease (aGVHD) is a primary
T cellemediated complication of allogeneic stem cell trans-
plantation (SCT), occurring when donor-derived T cells are
stimulated by host antigen-presenting cells (APCs), which
are enhanced by proinﬂammatory cytokines, such as IL-1, IL-
6, and TNF-a [1,2]. Recent studies have brought a renewed
focus on the previously unrecognized role of adaptive T cell
subsets and B cells in the induction and regulation of aGVHD
[1]. Several novel innate immune cell subtypes (monocytes,
dendritic cells [DCs], and NK cells) are known to affect the
intensity of immunologic reactions in GVHD [1,3,4].
However, the complex interactions involving the innate and
adaptive immune systems remain to be deﬁned to provide
a clearer understanding of the pathogenesis of aGVHD.
Pattern recognition receptors, such as Toll-like receptors
(TLRs), play a key role in the cross-talk between the innate and
adaptive immune systems [5,6]. TLRs belong to the type I
transmembrane glycoprotein receptor family and are
expressed by several cell types, including airway and epithelial
cells,NKcells,DCs,BandT lymphocytes,monocytes,mast cells,
macrophages, neutrophils, basophils, and endothelial cells [5-
7]. TLRs recognize pathogen-associated molecular patterns
(PAMPs), such as common protein, carbohydrate, and DNA/
RNA pattern motifs [5,6]. They also serve as receptors for
endogenous ligandsanddamaged tissues, suggesting thatbothdgments on page 233.
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12.09.013can trigger signals responsible for the regulation of innate and
adaptive immune responses [5,6]. Extracellular ligands are
recognized by surface TLRs (TLR-1, -2, -4, -5, and -6). Intracel-
lular TLRs (TLR-3, -7, -8, and -9) bindmainly to foreign nucleic
acids and sometimes detect self-DNA/RNA [5,6,8].
Very little is known about the in vivo expression and
function of TLRs in patients who undergo allogeneic SCT and
eventually develop aGVHD. The analysis of TLRs on cells of
the immune system could be useful for identifying
biomarkers of aGVHD and potential therapeutic targets.
Speciﬁc TLR agonists and antagonists have shown promising
results as immune-modulating agents in the treatment of
other immune disorders, including noninfectious inﬂam-
matory and autoimmune diseases [9]. Thus, we prospectively
evaluated the expression of TLR-1 to -9 on peripheral blood T
lymphocytes and monocytes in relation to the onset of
aGVHD. We also performed functional analysis after TLR
stimulation to assess activity. We focused the analysis on T
lymphocytes and monocytes, the former because they are
primarily involved and the latter because of their emerging
key role in the pathogenesis of aGVHD.
PATIENTS AND METHODS
Patients and Transplantation Procedures
Prospective evaluations of TLR expression and function were performed
in 34 patients who underwent allogeneic SCT. All patients provided written
consent in accordance with the Declaration of Helsinki and the Ethics
Committee of the Hospital “Spedali Civili.” Characteristics of the patients
and transplants are reported in Table 1.
Antibiotic prophylaxis with levoﬂoxacin was provided until complete
neutrophil recovery was observed. Fluconazole or itraconazole was admin-
istered until all immunosuppressive drugs were withdrawn. Trimethoprim-
sulphamethoxazole was given to prevent Pneumocystis carinii pneumonia.
Cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6) infections wereTransplantation.
Table 1
Patient and Transplant Characteristics
Characteristic Value
Age at SCT, years, median (range) 46.5 (18-64)
Sex, n (%)
Male 24 (71)
Female 10 (29)
Diagnosis, n (%)
Acute leukemia 15 (44)
NHL/CLL 8 (24)
Other 11 (32)
Donor, n (%)
Matched related donor 22 (65)
Matched unrelated donor 12 (35)
HLA match, n (%) 28 (82)
Conditioning, n (%)*
MAC 19 (56)
RIC 15 (44)
Antithymocyte globulin, n (%)
Yes 14 (41)
No 20 (59)
Stem cell source, n (%)
Peripheral blood 30 (88)
Bone marrow 4 (12)
CD34þ cell dose,  106/kg, median (range) 5 (1.1-7.9)
CD3þ cell dose,  107/kg, median (range) 20.7 (2.3-48.7)
GVHD prophylaxis with CyA þ MTX, n (%) 34 (100)
Bacterial infection before 30 days post-SCT, n (%) 18 (53)
IFI before 30 days post-SCT, n (%) 3 (9)
CMV infection before 30 days post-SCT, n (%) 5 (16)
HHV-6 infection before 30 days post-SCT, n (%) 2 (6)
aGVHD, n (%)
Yes 19 (56)
No 15 (44)
Grade II 11 (32)
Time, days, median (range) 28 (20-50)
CLL indicates chronic lymphoblastic leukemia; IFI, invasive fungal infection;
MAC, myeloablative conditioning; NHL, non-Hodgkin lymphoma; RIC,
reduced-intensity conditioning.
* Types of conditioning: MAC subtypes included total body irradiation (12
Gy in 6 fractions) þ cyclophosphamide (CY) in 6 patients and busulfan þ CY
in 13 patients. RIC subtypes included thiotepa þ ﬂudarabine þ CY in 7
patients, thiotepa þ CY in 6 patients, and thiotepa þ ﬂudarabine þ
melphalan in 2 patients.
C. Skert et al. / Biol Blood Marrow Transplant 19 (2013) 227e234228monitored weekly by quantitative real-time PCR in plasma, and patients who
tested were treated with ganciclovir or foscarnet. Fungal infections were
evaluated and deﬁned according to the revised criteria of the European
Organization for Research and Treatment of Cancer Invasive Fungal Infections
Cooperative Group/National Institute of Allergy and Infectious Diseases
Mycoses Study Group Consensus Group [10]. Bloodstream infection was
deﬁned according to the modiﬁed criteria of Poutsiaka et al. [11]. Bacterial
infections included all bloodstream infections with or without organ locali-
zation. Chimerism was assessed by the variable number tandem repeat PCR
test on peripheral blood mononuclear cells (PBMCs), polymorphonuclear
leukocytes, and lymphocytes. Diagnosis and grading of aGVHD were based
primarily on clinical ﬁndings according to commonly accepted diagnostic
criteria [12,13]. Whenever possible or necessary, the clinical data were sup-
ported by histopathologic ﬁndings of the skin, liver, and gastrointestinal tract.
aGVHD prophylaxis included 3 mg/kg/day cyclosporine A (CyA) i.v.
via continuous infusion starting on day -1 along with methotrexate (MTX)
15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6, and 11 in myeloablative
conditioning regimens, and 10 mg/m2 on day 1 and 8 mg/m2 on days 3 and 6
in reduced-intensity conditioning regimens. CyA was given orally in 2 doses
as soon as the patient was able to tolerate oral intake. CyA blood levels were
monitored daily by chemiluminescence microparticle immunoassay (Abbott
HematologyeDiagnostics Division, Santa Clara, CA). CyA dose was adjusted to
maintain blood levels between 150 and 250 ng/mL.Assessment of TLRs
To investigate a possible correlation between aGVHD and the expression
and function of TLRs in SCT recipients, we performed ﬂow cytometry anal-
ysis of TLR expression on monocytes and T lymphocytes, along with
a functional analysis by induction of cytokines from PBMCs on TLR stimu-
lation. The assessment of TLRs was planned at daysþ30,þ60, andþ90 post-
SCT and at the time of aGVHD onset; however, aGVHD developed before
day þ60 (median time, 28 days post-SCT) in all patients. Thus, theassessment was performed at the onset of aGVHD and at day þ30 for
patients without aGVHD. We assessed TLR-1, -2, -4, and -6 (expressed on
plasma membrane), receptors for lipid-based PAMPs; TLR-3, -7, -8, and -9
(expressed in cytoplasmic compartments), receptors for nucleic acidebased
PAMPs; and TLR 5, surface receptor for ﬂagellin of Gram-negative bacteria.
We did not assess TLR-10, because its agonist for functional analysis is
unknown and preliminary data on cell expression show no signiﬁcant
differences between patients with aGVHD and those without aGVHD. We
assessed these TLRs in 17 healthy donors as well.
Analysis of TLR Expression by Flow Cytometry
PBMCs from healthy donors and patients were isolated by Ficoll-Paque
density gradient centrifugation using standard procedures. Lymphocyte and
monocyte gates were identiﬁed on forward-scatter and side-scatter plots.
FITC-conjugated CD3 antibody (BD Biosciences, Mountain View, CA) was
used to identify T lymphocytes. PBMCs were incubated with anti-TLR Abs as
described below. Surface and intracellular staining was performed using PE-
conjugated Abs. TLR-2, -3, -4, -5, -6, -7, -8, and -9 antibodies were purchased
from Imgenex (San Diego, CA), and anti-TLR1 was obtained from e-Biosci-
ence (San Diego, CA). Human immunoglobulin vein solution (Kedrion, Lucca,
Italy) was used for FcR monocyte saturation to avoid binding of unspeciﬁc
antibodies. PE-conjugated IgG1 isotype antibody was used as a negative
control (BD Pharmingen, San Diego, CA).
For TLR-1,- 2, -4, -5 and -6, analysis was performed using the ﬂow
cytometric cell surface method. Cells were incubated for 30 minutes at 4C
in the dark, washed once with 2% FBS, and ﬁnally suspended with staining
buffer solution (Imgenex). Intracellular staining for TLR-3, -7, -8, and -9 was
performed using an Imgenex Intracellular Staining Flow Assay Kit according
to the manufacturer’s instructions. A minimum of 10,000 events were
acquired and analyzed in both monocyte and T lymphocyte gates using
a FACSCalibur ﬂow cytometer and CellQuest software (BD Biosciences). TLR
expression was evaluated as mean ﬂuorescence intensity (MFI), with
negative control MFI subtracted.
Functional Analysis of TLRs
The functional evaluation of TLRs was performed on total PBMCs to
avoid possible aspeciﬁc activation by cell selection procedures [14]. A total of
100,000 cells/well were plated in duplicate in 96-well round-bottomed
plates and stimulated by the following TLR agonists: Pam3CSK4 for
TLR-1/2, heat-killed preparation of Listeria monocytogenes for TLR-2,
Poly(I:C) Low Molecular Weight for TLR-3, Lipopolysaccharide for TLR-4,
ﬂagellin for TLR-5, FSL1 for TLR-6/2, imiquimod for TLR-7, ssRNA40 for
TLR-8, and ODN2006 for TLR-9 (InvivoGen, San Diego, CA). Stimuli were
used after dilution in endotoxin-free RPMI complete medium at ﬁnal
concentrations according to the manufacturer’s instructions. After 24 hours
of cell stimulation at 37C in a 5% CO2 atmosphere, the platewas centrifuged,
and conditioned media were harvested and stored at 20C before ELISA
assays. Supernatants were thawed at room temperature and assessed using
ELISA kits (Bender MedSystem, Vienna, Austria) according to the manufac-
turer’s instructions. The cytokines analyzed were IFN-g (Th1 cytokine), IL-4
(Th2 cytokine), TNF-a (proinﬂammatory cytokine), and monocyte chemo-
tactic protein 1 (MCP-1; C-C chemokine). Detection limits were as follows:
1.65 pg/mL for TNF-a, 2.31 pg/mL for MCP-1, 0.66 pg/mL for IL-4, and 0.99
pg/mL for IFN-g.
Results are reported as relative induction and expressed using the
following formula: (induction of cytokine with TLR ligand activation -
induction of cytokine of medium control)/induction of cytokine of
medium control.
Lymphocyte Count and Routine Immunophenotyping
Lymphocyte count and routine immunophenotyping were performed
by ﬂow cytometry in the laboratory of the University of Brescia’s Clinical
Biochemistry Department. Peripheral blood samples were collected and
incubated with pretitrated saturating dilutions of the following FITC- or
PE-conjugated mAbs: CD14, CD45, CD3, CD4, CD8, CD19, CD16, and CD56
(BD Biosciences). Samples were analyzed with a FACScan ﬂow cytometer
and CellQuest software (BD Biosciences).
Statistical Analysis
Univariate analysis of the variables in relation to the onset of aGVHDwas
performed using the Mann-Whitney U test and c2 test. The Mann-Whitney
U test was used to compare continuous values, and the c2 test was used to
compare differences in percentage. Monocyte count, lymphocyte subset
counts, TLR expression on monocytes and T lymphocytes, and cytokine
induction on TLR activation were analyzed. The following patient- and
transplant-related variables were also analyzed: age at SCT, sex, diagnosis,
type of donor, HLA mismatch, type of conditioning (reduced-intensity or
conventional myeloablative; chemotherapy-based or TBI-based), use of
Table 2
Comparison of Clinical Characteristics and Monocyte and Lymphocyte
Values in Patients with and without aGVHD
With
aGVHD
Without
aGVHD
P Value
(n ¼ 19) (n ¼ 15)
Age at SCT, years, median
(range)
48 (24-64) 44 (18-62) .57
Sex, n (%)
Male 13 (68) 11 (73) .95
Female 6 (32) 4 (27)
Diagnosis, n (%)
Acute leukemia 9 (47) 6 (40) .93
NHL/CLL 4 (21) 4 (27) .98
Other 6 (32) 5 (33) .80
Donor, n (%)
Matched related donor 13 (68) 9 (60) .88
Matched unrelated
donor
6 (32) 6 (40)
HLA mismatch, n (%) 4 (21) 2 (13) .89
Conditioning, n (%)*
MAC 12 (63) 7 (47) .49
RIC 7 (37) 8 (53)
Conditioning, n (%)y
Chemotherapy-based 16 (84) 12 (80) .89
Total body irradiatione
based
3 (16) 3 (20)
Antithymocyte globulin, n (%)
Yes 8 (42) 6 (40) .82
No 11 (58) 9 (60)
Stem cell source, n (%)
Peripheral blood 18 (95) 12 (80) .43
Bone marrow 1 (5) 3 (20)
CD34þ cell dose,  106/kg,
median (range)
5.1 (1.1-6.6) 4.8 (1.5-7.9) .58
CD3þ cell dose,  107/kg,
median (range)
18.2 (2.3-48.7) 21.9 (2.8-36.4) .81
Bacterial infection before
30 days post-SCT, n (%)
8 (42) 10 (67) .28
IFI before 30 days
post-SCT, (%)
1 (5) 2 (13) .83
CMV infection before
30 days post-SCT, n (%)
4 (21) 1 (7) .49
HHV-6 infection before
30 days post-SCT, n (%)
2 (11) 0 (0) .57
Lymphocytes, cells/mL,
mean  SD
CD3þ 380  261 552  465 .24
CD3þ/CD4þ 143  108 183  128 .40
CD3þ/CD8þ 213  146 344  403 .27
CD19þ 37  47 59  49 .21
CD16þ/CD56þ 115  132 144  52 .47
Monocytes, cells/mL,
mean  SD
480  363 539  277 .73
CLL indicates chronic lymphoblastic leukemia; IFI, invasive fungal infection;
MAC, myeloablative conditioning; NHL, non-Hodgkin lymphoma; RIC,
reduced-intensity conditioning.
* Types of RIC and MAC did not differ in patients with aGVHD and those
without aGVHD.
y Total body irradiation was used only in MAC.
Table 3
Comparison of TLR Expression on T Lymphocytes and Monocytes in Patients
with and without aGVHD
Without aGVHD (n ¼ 15) With aGVHD (n ¼ 19) P Value
T lymphocytes, MFI
TLR-1 4.3  2.9 (0.9-10.8) 1.6  2.2 (0-8.0) .02
TLR-2 1.2  0.8 (0-2.6) 1.4  0.9 (0-3.1) .53
TLR-3 1.6  1.1 (0-4.3) 1.3  1.2 (0-4.3) .50
TLR-4 1.8  1.3 (0-4.7) 1.7  1.3 (0-6.0) .74
TLR-5 1.9  1.6 (0-6.2) 3.5  2.3 (0.8-8.2) .03
TLR-6 1.9  1.8 (0-6.2) 2.6  2.1 (0.2-8.0) .38
TLR-7 2.9  1.7 (0.7-6.5) 2.0  2.1 (0-6.4) .16
TLR-8 0.8  1.7 (0-6.8) 0.5  0.6 (0-1.8) .61
TLR-9 108.8  51.5 (16.9-207.4) 63.8  50.4 (0-165) .01
Monocytes, MFI
TLR-1 54.9  37.4 (12.7-130.7) 21.4  21.9 (0.6-66.3) .005
TLR-2 4.9  3.6 (0-12.9) 7.9  10.5 (0.7-43) .50
TLR-3 4.1  1.9 (1.4-8.3) 3.1  1.9 (0-7.1) .15
TLR-4 11.1  8.3 (0-28.9) 10.8  6.9 (2.3-22.9) .91
TLR-5 9.0  4.7 (3.2-16.6) 25.8  24.3 (0.6-80) .01
TLR-6 9.2  6.5 (2.4-26.8) 10.9  12.4 (0-34.3) .40
TLR-7 7.0  4.4 (3.2-18.3) 4.6  3.9 (0-12.9) .14
TLR-8 1.9  1.7 (0-5.3) 1.3  1.4 (0-9.1) .22
TLR-9 168.5  77.9 (39.6-283.5) 85.3  73.9 (0-310) .002
MFI values are expressed as mean  standard deviation (range). Signiﬁcant
P values are in bold type.
C. Skert et al. / Biol Blood Marrow Transplant 19 (2013) 227e234 229antithymocyte globulin in conditioning, stem cell source, CD34 and CD3 cell
doses infused, and development of any bacterial, fungal, or viral infections
before TLR assessment (ie, before the onset of aGVHD and before day þ30
post-SCT in patients without aGVHD).
Principal component analysis (PCA) was performed as the ﬁrst step of
multivariate analysis to solve the problem of the high number of variables
compared with the relatively limited and heterogeneous pool of patients, as
described by Skert et al. [15]. PCA is typically used to reduce the dimen-
sionality of a large number of interrelated variables while retaining as much
information as possible [16]. Along with reducing a large dataset to a few
components that can be easily overviewed, PCA has important noise-
reducing properties in small populations of patients, analogous to the
reduction in noise gained by using large populations of patients. Thus, we
used PCA with varimax rotation to reduce the number of variables in rela-
tion to the number of patients and to perform a later multivariate analysis ofpredictor variables for aGVHD. PCA transforms a number of possibly corre-
lated variables into a smaller number of uncorrelated variables; these
principal components (PCs) are linear combinations of the original variables.
Each PC is a cluster of correlated variables. PCs are chosen in sequence as the
best descriptor of the data. The ﬁrst extracted PC accounts for the largest
part of the total variance in the dataset, the second PC has the second largest
amount of the variance, and so on for each subsequent component. The last
few PCs do not account formuch of the variance and thus can be ignored.We
used the eigenvalue-1 criterion (ie, Kaiser criterion) to select an adequate
number of PCs, with only PCs with eigenvalue >1 extracted. Only the vari-
ables with component loading >0.5 (absolute value) were included in each
PC extracted. Loadings vary in value from 1 to 1 and represent the degree
to which each of the variables correlates with each PC. Variables with
negative loadings have a meaning opposite to that of variables with positive
loadings.
Multivariate analysis was completed by multifactor analysis of variance
(ANOVA) using the PC scores, which were values of the PCs extracted by PCA
for each patient. All P values were 2-sided, and a P value <.05 was consid-
ered statistically signiﬁcant.
RESULTS
Clinical Characteristics of Patients with aGVHD
Nineteen patients (56%) developed aGVHD at a median
time of 28 days (range, 20-50 days) after SCT. The aGVHDwas
at least grade II in 11 patients (32%) and grade III in 3 patients
(9%). The most common target of aGVHD was skin, in 84% of
cases, with gastrointestinal tract and liver involved in 32%
and 16% of cases, respectively.
Eight patients (42%) had a bacterial infection, and 1
patient (5%) had an invasive fungal infection. CMV and HHV-
6 infections were detected in 4 (21%) and 2 (11%) patients,
respectively (Table 2).
TLR Expression on Monocytes and T Lymphocytes
The analysis of TLR expression on monocytes and T
lymphocytes was performed by ﬂow cytometry in 17 healthy
donors at the onset of aGVHD and at day þ30 in patients
without aGVHD. The median time of aGVHD onset was 28
days post-SCT. All patients achieved stable full chimerism at
the time of TLR assessment. The analysis of TLRexpression did
not show signiﬁcant differences between healthy donors and
patients without aGVHD (data not shown). Data on TLR
expression in SCT recipients are summarized in Table 3.
In patients with aGVHD, monocytes and T lymphocytes
Figure 1. Expression of TLR-1, -5, and -9 on T lymphocytes and monocytes. Histogram plots of TLR-1, -5, and -9 expression in a patient with aGVHD and in a patient
without aGVHD. The expression of surface (TLR-1 and -5) and intracellular (TLR-9) TLRs is reported with the corresponding negative control (mouse IgG1-PE). MFI is
shown for each histogram. T lymphocytes of the patient with aGVHD have higher MFI values of TLR-5 and lower MFI values of TLR-1 and -9 compared with the patient
without aGVHD (A). An analogous TLR proﬁle is displayed by monocytes (B).
C. Skert et al. / Biol Blood Marrow Transplant 19 (2013) 227e234230expressed lower levels of TLR-1, a surface receptor for lipid-
based PAMPs (P ¼ .005 and .02, respectively), and TLR-9,
an intracellular receptor for nucleic acidebased PAMPs(P ¼ .002 and .01, respectively), whereas levels of TLR-5,
a surface receptor for ﬂagellin of Gram-negative bacteria,
were signiﬁcantly increased (P ¼ .01 and .03, respectively).
Ta
b
le
4
C
om
p
ar
is
on
of
C
yt
ok
in
e
Re
la
ti
ve
In
d
u
ct
io
n
on
TL
R
A
ct
iv
at
io
n
in
Pa
ti
en
ts
w
it
h
an
d
w
it
h
ou
t
aG
V
H
D
IF
N
-g
(r
el
at
iv
e
in
d
u
ct
io
n
)
M
C
P-
1
(r
el
at
iv
e
in
d
u
ct
io
n
)
TN
F-
a
(r
el
at
iv
e
in
d
u
ct
io
n
)
W
it
h
ou
t
aG
V
H
D
(n
¼
15
)
W
it
h
aG
V
H
D
(n
¼
19
)
P
W
it
h
ou
t
aG
V
H
D
(n
¼
15
)
W
it
h
aG
V
H
D
(n
¼
19
)
P
W
it
h
ou
t
aG
V
H
D
(n
¼
15
)
W
it
h
aG
V
H
D
(n
¼
19
)
P
TL
R
-1
23
7

55
3
(0
-1
48
4)
77

15
7
(
1
to
47
2)
.5
2
22
10

60
79
(
0.
4
to
18
,3
70
)
11
17

35
24
(
1
to
11
,7
39
)
.6
7
66
7

19
64
(
0.
4
to
59
02
)
1.
4

3.
1
(
1
to
10
)
.3
2
TL
R
-2
98
3

17
70
(0
.3
-4
92
3)
74

21
9
(
1
to
69
8)
.0
3
14
,1
76

29
,5
34
(
0.
1
to
84
,2
40
)
29
75

86
01
(
0.
9
to
27
,3
91
)
.2
5
16
64

46
44
(
0.
4
to
14
,0
40
)
10

18
(
1
to
56
)
.1
2
TL
R
-3
24
1

42
7
(
0.
3
to
11
24
)
0
.4

0.
5
(
1
to
0)
.0
08
42
87

11
,8
38
(
0.
9
to
35
,8
15
)
91
6

20
95
(
1
to
64
60
)
.2
9
5.
2

9.
1
(
0.
3
to
26
)
0.
3

1.
1
(
1
to
3)
.3
1
TL
R
-4
86
8

17
71
(0
-4
82
3)
54

92
(
1
to
21
7)
.0
4
32
11

53
75
(
0.
2
to
14
,3
48
)
30
35

58
84
(
1
to
15
,4
20
)
.9
9
16
17

39
50
(
0.
1
to
11
,9
55
)
38

81
(
1
to
24
1)
.0
8
TL
R
-5
59
7

15
61
(
1
to
41
37
)
18
4

50
3
(
1
to
16
04
)
.8
0
12
,1
96

30
,6
30
(
0.
4
to
92
,4
46
)
17
65

39
19
(
1
to
11
,9
56
)
.6
6
89
7

25
75
(
1
to
77
63
)
2.
1

5.
6
(
1
to
19
)
.0
9
TL
R
-6
0
.1

0.
4
(
1
to
0.
3)
3.
5

8.
3
(
1
to
23
.9
)
.8
3
35
24

78
17
(0
.2
to
23
,2
06
)
80
4

24
95
(
0.
8
to
83
15
)
.8
8
39

64
(
0.
9
to
15
7)
2.
2

4.
5
(
1
to
13
.4
)
.1
6
TL
R
-7
53
7

13
68
(
1
to
36
37
)
3.
9

13
(
1
to
42
)
.2
9
42
22

11
,8
71
(
0.
4
to
35
,8
20
)
60

16
1
(
1
to
54
3)
.2
9
11
2

29
5
(
1
to
78
0)
0.
7

2.
4
(
1
to
8)
.4
5
TL
R
-8
94
1

18
45
(0
-4
86
4)
19
5

61
1
(
1
to
19
34
)
.1
5
11
50

30
20
(
0.
3
to
91
41
)
19
26

56
33
(
1
to
17
,9
20
)
.4
0
20
79

57
54
(
0.
7
to
16
,3
20
)
18

48
(
1
to
16
1)
.4
3
TL
R
-9
3.
4

8.
3
(0
-2
1)
0.
3

2.
6
(
1
to
8)
.0
4
55
5

10
40
(0
-2
55
4)
10
67

31
99
(
0.
9
to
10
,1
63
)
.4
5
50

11
8
(0
-3
38
)
18

60
(
1
to
20
0)
.0
7
R
el
at
iv
e
in
d
u
ct
io
n
¼
(i
n
d
u
ct
io
n
of
cy
to
ki
n
e
w
it
h
TL
R
lig
an
d
ac
ti
va
ti
on
-
in
d
u
ct
io
n
of
cy
to
ki
n
e
of
m
ed
iu
m
co
n
tr
ol
)/
in
d
u
ct
io
n
of
cy
to
ki
n
e
of
m
ed
iu
m
co
n
tr
ol
.V
al
ue
s
of
re
la
ti
ve
in
d
u
ct
io
n
ar
e
ex
p
re
ss
ed
as
m
ea
n

st
an
d
ar
d
d
ev
ia
ti
on
(r
an
ge
).
Si
gn
iﬁ
ca
n
t
P
va
lu
es
ar
e
in
bo
ld
ty
p
e.
C. Skert et al. / Biol Blood Marrow Transplant 19 (2013) 227e234 231Representative histogramplots of TLR-1, -5, and -9 expression
are shown in Figure 1.
Functional Analysis of TLR
We analyzed cytokine induction from PBMCs on TLR
stimulation concomitantly with ﬂow cytometry analysis. All
TLR agonists induced the production of IFN-g, TNF-a, and
MCP-1 in both healthy donors and SCT recipients, whereas
IL-4 production was not induced. Results are reported in
Table 4 as relative induction: (induction of cytokine with TLR
ligand activation - induction of cytokine of medium control)/
induction of cytokine of medium control. Healthy donors and
patients without aGVHD did not differ in terms of cytokine
production (data not shown). Patients with aGVHD had
lower IFN-g relative induction on stimulation with HKLM
(TLR-2 ligand; P ¼ .03) and LPS (TLR-4 ligand; P ¼ .04).
IFN-g relative induction was also decreased in patients with
aGVHD in response to LMW (TLR-3 ligand; P ¼ .008) and
ODN2006 (TLR-9 ligand; P ¼ .04).
Univariate and Multivariate Analyses of Predictor
Variables for aGVHD
In univariate analysis, clinical and transplant character-
istics, monocyte count, and lymphocyte subset counts were
not signiﬁcantly different in patients with aGVHD and those
without aGVHD (Table 2). Moreover, the 2 groups demon-
strated no signiﬁcant differences in terms of immunosup-
pressive therapy (MTX doses and CyA blood levels) and type
of reduced-intensity or myeloablative conditioning regimens
(data not shown). Monocytes and T lymphocytes of patients
with aGVHD had an analogous proﬁle, expressing higher
levels of TLR-5 and lower levels of TLR-1 and -9. These
patients also had lower IFN-g relative induction.
A 2-step multivariate analysis with PCA and multifactor
ANOVAwas used to solve the problem of the high number of
variables in comparison with the relatively limited and
heterogeneous pool of patients. Four clusters of variables (Cs)
were identiﬁed by PCA, with each cluster including only
variables with loading >0.5 (Figure 2). On multifactor
ANOVA, C2, C3, and C4 were signiﬁcantly associated with the
onset of aGVHD (Table 5). C2 included levels of TLR-5
expression on monocytes and T lymphocytes associated
with the development of aGVHD (positive loading). Levels of
TLR-9 and -1 on monocytes and T lymphocytes (C3 and C4,
respectively) were inversely correlated with aGVHD (nega-
tive loading). In summary, multivariate analysis with PCA
and multifactor ANOVA conﬁrmed the results of univariate
analysis, except for the negative correlation of IFN-g relative
induction.
DISCUSSION
TLRs are involved in maintaining immune tolerance and
eliminating pathogenic microorganisms [5,6]. They also play
a role in amplifying immune response in several inﬂamma-
tory diseases, including systemic lupus erythematosus (SLE),
arthritis, and inﬂammatory bowel disease, which have
similarities to GVHD [5,6,17,18].
Previous studies dealing with TLRs and aGVHD in SCT
recipients and mouse models have focused mainly on TLR-4
and -9 and have reported contrasting results [3,19-28]. To
our knowledge, no studies to date have examined the
expression and functionof all humanTLRs together in relation
to aGVHD, even in a single-cell subset of the immune system.
Thus,weperformed aprospective studycorrelating aGVHD to
expression of TLR-1 to -9 and cytokine production on
Figure 2. Clusters of variables identiﬁed by PCA after SCT. In the ﬁrst step of the multivariate analysis, 4 clusters of variables were extracted by PCA. The position of
each variable in the loading plot indicates its relationship with each cluster. Only variables with component loading >0.5 (absolute value) are included in each cluster.
Loadings vary in value from 1 to 1 and represent the degree to which each of the variables correlates with each cluster. Variables with negative loadings have
a meaning opposite to that of variables with positive loadings. C, cluster of variables; L, loading;B, variables included in C1;C, variables included in C2;,, variables
included in C3; -, variables included in C4. TLR-x (x ¼ 1, 5, or 9) (Mo) represents TLR-x expression on monocytes; TLR-x (x ¼ 1, or 5, or 9) (T-ly) represents TLR-x
expression on T lymphocytes.
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of peripheral blood, with T lymphocytes primarily involved
and the role of monocytes in the pathogenesis of aGVHD
becoming increasingly evident [1,4,29]. Although monocytes
function as weaker APCs compared with DCs, they may
differentiate to DCs when exposed to inﬂammatory stimuli
[30,31]. Monocytes may contribute to tissue damage through
their effector functions, such as production of TNF-a and O2
radicals, or by stimulating effector T lymphocytes [32,33].
Our 2-step multivariate analysis revealed a signiﬁcant
correlation between aGVHD and a similar TLR expression
proﬁle on monocytes and T lymphocytes, which were
characterized by higher levels of TLR-5 and lower levels of
TLR-1 and -9.
TLR-5 detects ﬂagellin, a protein that autopolymerizes to
form the ﬂagella of a wide variety of pathogenic and
nonpathogenic bacteria, including those of intestinal micro-
biota [5,6]. The interaction between TLR-5 and ﬂagellin in
monocytes and lymphocytes may be a critical point in the
pathogenesis of aGVHD, with intestinal microﬂora playing
a known role in its development [1-3]. Furthermore, immune
cells also may encounter ﬂagellin following the bacterial
translocation from the bowel lumen to the systemic circu-
lation [3]. Increased expression of TLR-5 on monocytes has
been associated with increased inﬂammatory responses in
elderly individuals [34] and in patients with SLE [35], similar
to our results in patients with aGVHD. Increased expression
of TLR-5 on monocytes could induce their differentiation in
M1 macrophages and in immunogenic APCs/DCs, withTable 5
Clusters of Variables Correlated with aGVHD by Multifactor ANOVA
Cluster P Value
C1 (IFN-g relative induction on TLR-2, -3, -4, and
-9 stimulation)
.16
C2 (TLR-5/Mo, TLR-5/T-ly) .01
C3 (TLR-9/Mo, TLR-9/T-ly) .01
C4 (TLR-1/Mo, TLR-1/T-ly) .03
TLR-x (x¼ 1, 5, or 9)/Mo: TLR-x expression onmonocytes; TLR-x (x¼ 1, 5, or
9)/T-ly: TLR-x expression on T lymphocytes. Four clusters of variables were
identiﬁed by PCA. IFN-g relative induction on TLR stimulation and TLR
expression on monocytes and on T lymphocytes included in each cluster are
in parentheses. C2, C3, and C4 are correlated with aGVHD. Signiﬁcant P
values are in bold type.a consequent Th1 cell response [33,36]. Overexpression of
TLR-5 on monocytes could alter its intracellular trafﬁcking
and localization, leading to a shift from an overall anti-
inﬂammatory to an overall proinﬂammatory immune
response. In fact, there is evidence suggesting that changes in
intracellular trafﬁcking of extracellular TLRs may activate
different signaling pathways and consequently regulate the
type and intensity of immune responses [37].
The expression and function of TLR-5 on lymphocytes
have been analyzed in several previous studies that focused
mainly on T cells of healthy donors or of patients with
autoimmune/inﬂammatory diseases [7,35,38-42]. We found
higher TLR-5 expression on T lymphocytes of patients with
aGVHD. Both effector and regulatory T cells (Tregs) express
TLR-5 at physiologically relevant levels, explaining in part its
ambivalent immunoregulatory/immunostimulatory function
[39-42]. TLR-5 stimulation may enhance the suppressive
capacity of Tregs and the proliferation/activation of effector T
cells, especially of memory T cells, balancing immune
responses in physiological conditions [39,42]. In aGVHD, this
homeostatic mechanism may break down, because an
ampliﬁed inﬂammatory environment may persist and
effector T cells may prevail over Tregs. Inﬂammatory cyto-
kines and costimulatory molecules may lead to strong acti-
vation of effector T cells, which would maintain their
resistance to Treg suppression [39].
Immune reactions in aGVHD could be promoted by
decreased expression of TLR-1, which works as a hetero-
dimer with TLR-2 to recognize lipopeptides of different
pathogens, including bacteria, fungi, and viruses [5,6]. As
a heterodimer with TLR-2, TLR-1 may inﬂuence the response
to endogenous danger signals from injured tissue, such as
heat shock proteins and high-mobility group box 1 proteins
[5,6]. In monocytes, decreased surface expression of TLR-1
could preferentially activate the canonical nuclear factor-kB
pathway, resulting in the induction of inﬂammatory cyto-
kines and immunogenic APC maturation [43,44]. Previous
studies have shown that TLR-2emediated stimulation of
Tregs inﬂuences their expansion and functions [40,45]; thus,
a defective TLR-2/1 heterodimer stimulation could dysregu-
late the proliferative and suppressive efﬁciency of Tregs.
TLR-9 signaling may function as dampener or promoter of
immune reactions, likely with a prevalence of protective
C. Skert et al. / Biol Blood Marrow Transplant 19 (2013) 227e234 233effects in autoimmune diseases. Opposite effects of TLR-9 in
the pathogenesis of GVHD have been demonstrated inmouse
models and SCT recipients [3,21-23,26,27], whereas only 1
previous study correlated TLR-9 high-expressing B cells with
the onset of extensive chronic GVHD [46].
TLR-9 recognizes double-stranded DNA viral, protozoan,
and bacterial genoma [5,6]. Phosphorothioate linkages and
unmethylated CpG motifs, which are lacking in mammalian
DNA, are not the only foreign signature that triggers TLR-9
[8]. Localization of DNA in the endosomal compartment,
rather than its sequence, species origin, covalent modiﬁca-
tion, or double versus single strandedness, triggers TLR-9
activation [8]. Endogenous DNA can indeed stimulate TLR-9
activation, especially in abnormal conditions, as occurs in
SLE, whereas under normal conditions, endogenous nucleic
acids hardly gain access to the intracellular compartment
[5,8,17,18]. Self-derived nucleic acids can bypass this
protectivemechanism in conditions of abundant autoantigen
release, such as tissue injury, increased apoptosis, defective
clearance of cell debris, or inﬂammatory states [8,17,18,47].
Furthermore, in inﬂammatory milieu, oxidation of DNA/RNA
by reactive oxygen species and hypomethylated DNA
deriving from mitochondrial damage may lead to increased
immunogenicity of self-nucleic acids [18,48]. All of these
conditions may characterize aGVHD and thus may explain
TLR-9 involvement, even in the absence of viral or bacterial
infections. Patients with aGVHD expressed lower levels of
TLR-9 on both monocytes and T lymphocytes, highlighting
TLR-9’s potential protective role. TLR-9 shares a common
signaling pathway with TLR-7 and TLR-8, which induces
proliferation and cytokine release in B cells, T cells, IFN-a, and
proinﬂammatory cytokines in plasmacytoid DCs [8,18]. These
cytokines may promote myeloid DC differentiation and T cell
activation. Activation of this signaling pathway should
produce an overall inﬂammatory/immunostimulatory effect,
in contrast with the emerging protective role of TLR-9, as
shown by our results and those of others [17,18,47]. Emerging
evidence shows that the prevalence of TLR-9 stimulation
may inhibit TLR-7 activation by RNA complexes [18,47] and
its univocal proinﬂammatory effects on monocytes, which
also promotes their differentiation in tolerogenic DCs. The
antagonism with TLR-7 could positively modulate Treg efﬁ-
ciency [18,47]. Thus, decreased expression of TLR-9 could
shift the balance toward a prevalence of TLR-7 activation and
of the proinﬂammatory pathway.
Our multivariate analysis did not conﬁrm IFN-g induction
on the activation of TLR-2, -3, -4, or -9 as a negative predictor
of aGVHD. Furthermore, the different expression of TLRs in
patients with aGVHD was not always related to changes in
cytokine production. On the other hand, in vitro analysis of
cytokine production can provide only a partial assessment of
the effects of TLR activation, taking into account the different
functions of TLRs in the cells of the immune system.
In conclusion, both monocytes and T lymphocytes were
characterized by an analogous TLR proﬁle (including TLR-1,
-5 and -9 expression), which likely promotes an overall
immunostimulatory/proinﬂammatory response. Changes in
TLR expression and correlated signaling pathways could
modulate the type and the intensity of immune reactions by
interacting not only with microbial agents, but also with
endogenous danger signals of damaged tissues, such as self-
DNA, heat shock proteins, and high-mobility group box 1
protein.
In this preliminary study, PCA was used to overcome the
problem deriving from the high number of variablescomparedwith the relatively limited pool of patients. Studies
involving a larger number of patients would be useful to
conﬁrm our ﬁndings, and to validate this TLR proﬁle as
a biomarker of aGVHD. Furthermore, studies on different
lymphocyte subsets could help clarify the roles of TLR-1, -5,
and -9 in adaptive immunity in the setting of aGVHD.
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